Dear Editor, Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a form of autoimmune encephalitis involving anti-NMDAR antibodies, which is specific to the NR1/NR2 heteromers of the NMDAR.
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The correlation between anti-NMDAR encephalitis and SLE is yet to be clarified. Previous studies have found autoantibodies to an NR2 peptide of NMDAR in 25-30% of SLE patients, and these autoantibodies might play a role in cognitive dysfunction and psychiatric disease. 5, 6 DeGiorgio et al. 7 showed that lupus antibodies could cross-react with the NMDA receptor, and could mediate neural death via an apoptotic pathway.
Mackay et al. 8 described two patients presenting with progressive cognitive dysfunction and NMDAR antibodies with sporadic Creutzfeldt-Jakob disease (CJD). Those authors suggested that the immune response was due to NMDA receptors released from damaged neurons, and further believed that a positive antibody test did not exclude CJD. Anti-NM-DAR encephalitis and NPSLE have previously been demonstrated to be associated with the NR1 subunit and NR2 subunit, respectively. Ogawa et al. 9 showed that autoantibodies to the NMDAR NR1 subunit were expressed in SLE, especially in NPSLE. They also suggested that autoantibodies to that subunit could be involved in the pathogenesis of NPSLE. Our case showed weak positivity for anti-NMDAR antibodies in both serum and CSF. Zandi et al. 10 mentioned that weak positivity is unlikely to mislead clinicians, but it could result in an opportunity for treatment being missed. Therefore, further studies are required to delineate the mechanism of anti-NMDAR encephalitis with SLE.
The treatment for SLE-associated anti-NMDAR encephalitis has not been established conclusively. The conventional recommended treatment for anti-NMDAR encephalitis is methylprednisolone plus immunoglobulin or plasma exchange as the first-line therapy, and rituximab, cyclophosphamide, or their combination as the second-line therapy. 3 In the US, only three compounds have been approved by the Food and Drug Administration for SLE treatment: glucocorticoids, aspirin, and hydroxychloroquine. 5 Cyclophosphamide is the only drug used to treat SLE in cases of organ-threatening disease.
The present case is a reminder that SLE with seizures could lead to a diagnosis of NPSLE and also of anti-NMDAR encephalitis. This case and previous reports suggest that SLE is an indicator in the development of anti-NMDAR encephalitis. Whether lupus antibodies cross-react with NMDAR-possibly resulting in neuropsychiatric disorders-should be fur- 
